GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Farmaceutica Remedia SA (BSE:RMAH) » Definitions » Cyclically Adjusted Revenue per Share

Farmaceutica Remedia (BSE:RMAH) Cyclically Adjusted Revenue per Share : lei4.93 (As of Jun. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Farmaceutica Remedia Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Farmaceutica Remedia's adjusted revenue per share for the three months ended in Jun. 2024 was lei1.461. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is lei4.93 for the trailing ten years ended in Jun. 2024.

During the past 12 months, Farmaceutica Remedia's average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-09-25), Farmaceutica Remedia's current stock price is lei0.72. Farmaceutica Remedia's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was lei4.93. Farmaceutica Remedia's Cyclically Adjusted PS Ratio of today is 0.15.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Farmaceutica Remedia was 0.29. The lowest was 0.14. And the median was 0.16.


Farmaceutica Remedia Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Farmaceutica Remedia's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Farmaceutica Remedia Cyclically Adjusted Revenue per Share Chart

Farmaceutica Remedia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 3.75 4.17 4.64

Farmaceutica Remedia Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.44 4.55 4.64 4.83 4.93

Competitive Comparison of Farmaceutica Remedia's Cyclically Adjusted Revenue per Share

For the Medical Distribution subindustry, Farmaceutica Remedia's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Farmaceutica Remedia's Cyclically Adjusted PS Ratio Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Farmaceutica Remedia's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Farmaceutica Remedia's Cyclically Adjusted PS Ratio falls into.



Farmaceutica Remedia Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Farmaceutica Remedia's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=1.461/132.5538*132.5538
=1.461

Current CPI (Jun. 2024) = 132.5538.

Farmaceutica Remedia Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 0.530 100.428 0.700
201412 0.657 99.070 0.879
201503 0.590 99.621 0.785
201506 0.486 100.684 0.640
201509 0.584 100.392 0.771
201512 0.596 99.792 0.792
201603 0.480 100.470 0.633
201606 0.531 101.688 0.692
201609 0.633 101.861 0.824
201612 0.765 101.863 0.995
201703 0.715 102.862 0.921
201706 0.778 103.349 0.998
201709 0.827 104.136 1.053
201712 1.000 104.011 1.274
201803 0.947 105.290 1.192
201806 1.046 106.317 1.304
201809 1.154 106.507 1.436
201812 1.235 105.998 1.544
201903 1.009 107.251 1.247
201906 0.982 108.070 1.204
201909 1.025 108.329 1.254
201912 1.200 108.420 1.467
202003 1.445 108.902 1.759
202006 0.783 108.767 0.954
202009 1.058 109.815 1.277
202012 1.027 109.897 1.239
202103 1.344 111.754 1.594
202106 0.999 114.631 1.155
202109 1.305 115.734 1.495
202112 1.400 117.630 1.578
202203 1.286 121.301 1.405
202206 1.431 125.017 1.517
202209 1.374 125.227 1.454
202212 1.517 125.222 1.606
202303 1.431 127.348 1.489
202306 1.532 128.729 1.578
202309 1.445 129.860 1.475
202312 1.805 129.419 1.849
202403 1.814 131.776 1.825
202406 1.461 132.554 1.461

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Farmaceutica Remedia  (BSE:RMAH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Farmaceutica Remedia's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.72/4.93
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Farmaceutica Remedia was 0.29. The lowest was 0.14. And the median was 0.16.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Farmaceutica Remedia Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Farmaceutica Remedia's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Farmaceutica Remedia Business Description

Industry
Traded in Other Exchanges
N/A
Address
No. 2 Nicolae Balcescu Boulevard, Hunedoara County, Deva, ROU, 330040
Farmaceutica Remedia SA is engaged in drug sales activities, marketing, and health products. It provides marketing and promotion services for medicines. The company offers services offered, including logistics services, medical marketing, and promotion, and pharmaceutical registrations, but also professionalism and performance differentiate the company from other competitors and position it as a partner for launching, promoting, and distributing pharmaceutical products in Romania and other countries in Eastern Europe.

Farmaceutica Remedia Headlines

No Headlines